ABIVAX Société Anonyme Management

Management Kriterienprüfungen 1/4

ABIVAX Société Anonyme CEO ist Marc M. de Garidel , ernannt in May 2023, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.061% der Aktien des Unternehmens, im Wert von €366.57K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.5 Jahre bzw. 4.8 Jahre.

Wichtige Informationen

Marc M. de Garidel

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.8yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Marc M. de Garidel (65 yo)

less than a year

Amtszeit

Mr. Marc M. P. de Garidel, M.B.A., serves as CEO & Interim Chair of Board at ABIVAX Société Anonyme since May 5, 2023. He has been the Chief Executive Officer of CinCor Pharma, Inc. since July 2021 and has...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philippe Pouletty	Founder & Director	no data	keine Daten	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	keine Daten	0.061% € 366.6k
Didier Blondel	EVP, CFO & Board Secretary	6.9yrs	keine Daten	0.00060% € 3.6k
Didier Scherrer	Chief Scientific Officer	less than a year	keine Daten	0.057% € 343.8k
Patrick Malloy	Senior Vice President of Investor Relations	less than a year	keine Daten	keine Daten
Ida Hatoum	Chief People Officer	less than a year	keine Daten	keine Daten
Pierre Courteille	Chief Business Officer	no data	keine Daten	0% € 0
Jérôme Denis	Executive Vice President of Process Development & Manufacturing	less than a year	keine Daten	keine Daten
Sheldon Sloan	Chief Medical Officer	less than a year	keine Daten	keine Daten
Michael Ferguson	Chief Commercial Officer	less than a year	keine Daten	keine Daten

0.5yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: ABVXpDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philippe Pouletty	Founder & Director	9yrs	keine Daten	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	keine Daten	0.061% € 366.6k
Christian Brechot	Member of Scientific Advisory Board	6.2yrs	keine Daten	keine Daten
Christian Trepo	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Lawrence Stanberry	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Troy Ignelzi	Independent Director	less than a year	keine Daten	keine Daten
Christoph Huber	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Claude Bertrand	Member of Scientific Advisory Board	4.2yrs	€4.94k	keine Daten
Luc Teyton	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
June Lee	Independent Director	less than a year	keine Daten	keine Daten
Corinna Bonsen-Thomas	Independent Non-Executive Director	6.5yrs	€22.89k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	5.5yrs	keine Daten	keine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

64.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ABVXpDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).

ABIVAX Société Anonyme Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter